# Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

> **NCT04029116** · PHASE3 · COMPLETED · sponsor: **Scynexis, Inc.** · enrollment: 440 (actual)

## Conditions studied

- Recurrent Vulvovaginal Candidiasis

## Interventions

- **DRUG:** Fluconazole Tablet
- **DRUG:** IBREXAFUNGERP
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04029116
- **Lead sponsor:** Scynexis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-21
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-11-29
- **Target enrollment:** 440 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04029116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04029116, "Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04029116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*